• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 7th May 2013

Valuing Orphan Medicines Using Multi-Criteria Decision Analysis

OHE has just released a research paper that describes an experimental study intended to test whether and how a multi-criteria decision analysis (MCDA) approach can be applied to orphan medicinal products (OMPs). OHE has just released a research paper that…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
Multi-criteria-decision-Sussex-RP-2013-BIG

OHE has just released a research paper that describes an experimental study intended to test whether and how a multi-criteria decision analysis (MCDA) approach can be applied to orphan medicinal products (OMPs).

Multi-criteria-decision-Sussex-RP-2013-BIG

OHE has just released a research paper that describes an experimental study intended to test whether and how a multi-criteria decision analysis (MCDA) approach[1] can be applied to orphan medicinal products (OMPs). To be successful, the project had to both establish an explicit framework for defining the value of OMPs and provide an explicit understanding of the trade-offs that must be made in coverage decisions.

In all health care systems, HTA and reimbursement decisions begin with an assessment of value. Many systems take a distinct approach where orphan medicines are concerned. Policy makers and payers continue in seek improvements in approaches to determining the value of medicines. The move towards “value based pricing” in the UK is just one example. As yet, however, no HTA agency explicitly uses MCDA. This method applies more than one criterion to establish value and explicitly identifies the impact and relative importance of each criterion on a decision. Trades offs across attributes is characteristic of this approach; more of one attribute can compensate for less of another.

The purpose of this research was to identify which attributes to include in an OMP value framework, determine their relative importance using an MCDA process, and test whether an MCDA approach can provide a practical aid to decision making.

The project included both literature reviews and workshops. Literature searches were completed for the natural history and burden of 40 rare diseases and for how payers assess treatment value. The three workshops included, respectively (1) GlaxoSmithKline managers working on OMPs, (2) EU clinical and health economics experts, and (3) rare disease patients’ groups based in the EU. Participants refined the attributes, weighted them, scored two case study OMPs on those attributes, and tested the sensitivity of the overall ratings to changes in weights and scores.

Eight non-monetary attributes were agreed: four focussed on the disease being treated and four addressing the treatment itself. Workshop participants reached consensus on the weights for the attributes. The patients’ group representatives and the clinical and health economics experts both assigned about half of the weight to attributes reflecting the disease being treated and half to attributes of the treatment. Patients’ group representatives, however, gave greater weight than the experts to the patient’s quality of daily life and less weight to clinical factors. The weighted attributes proved usable in practice; they readily were applied by workshop participants to two example OMPs and yielded distinct value ratings.

From this project, we conclude that an OMP value framework with agreed attributes and weights is a viable proposition using an MCDA approach. Moreover, it could improve clarity and transparency in decision making about the value of OMPs.

[1] For a thorough discussion of MCDA and its uses, see Devlin, N.J. and Sussex, J. (2011) Incorporating multiple criteria in HTA: Methods and processes. London: Office of Health Economics. The publication may be downloaded from this website by registered users.

Download: Sussex, J., Rollet, P., Garau, M., Schmitt, C., Kent, A. and Hutchings, A. Multi-criteria decision analysis to value orphan medicines. Research Paper 13/03. London: Office of Health Economics.

For additional information, please contact Jon Sussex.

  • Health Technology Assessment…
  • Value, Affordability, and…
  • Research Papers

Related News

  • News
  • December 2020

Should We ‘Drop Dead’ from Health State Valuation?

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • January 2020

Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead

Read more
  • News
  • September 2019

HTA and Payment Mechanisms for New Drugs to Tackle AMR

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!